
EU Publishes Second Revision of MDCG 2023-3: Key Updates for Manufacturers
The European Commission has released the second revision of the MDCG 2023-3 guidance document in January 2025. This update includes important clarifications in line with Regulation (EU) 2024/1860, affecting the implementation of Eudamed, post-market surveillance, and reporting timelines. Below, we summarize the key changes:
- Alignment with Regulation (EU) 2024/1860
Footnote 8 has been amended to align with Regulation (EU) 2024/1860, which introduces a gradual roll-out of Eudamed. Additionally, it clarifies the obligation to inform authorities in case of supply interruptions or discontinuations and provides transitional provisions for specific in vitro diagnostic medical devices (IVDs). - Terminology Update for Eudamed Vigilance Module
In Question 21, the reference to ‘Eudamed vigilance (VGL) module’ has been updated to ‘Eudamed Post-market surveillance and Vigilance module (VGL module)’. This change reflects a broader scope of post-market surveillance requirements within Eudamed. - Clarification on Reporting Timelines
Footnote 34 has been revised to replace ‘48 working hours’ with ‘allow 48 hours (equivalent to two weekdays)’. This clarification ensures a consistent interpretation of reporting deadlines.
These updates highlight the ongoing efforts of the European Commission to refine regulatory guidance and improve clarity for manufacturers and stakeholders.
For detailed information, refer to the full guidance document: MDCG 2023-3 Rev.2.
MedNet EC-REP GmbH remains committed to supporting medical device and IVD manufacturers in navigating regulatory changes. For questions regarding Eudamed requirements or compliance, feel free to contact us.
Latest news
%20(1)-250x250.jpg&w=256&q=75)
MedNet EC-REP at MedTec Japan 2025 – Meet Us at Booth 3303
We are pleased to announce our participation as an exhibitor at MedTec Japan 2025, one of Asia’s leading trade shows for medical device design and manufacturing. The event will take place in Tokyo from April 17–19, 2025.

Swissmedic Highlights Post-Market Surveillance Obligations for Legacy Devices
Swissmedic has released findings from a recent focused action, underscoring the critical importance of robust Post-Market Surveillance (PMS) for all medical devices.

EU Commission Updates Guidance on SARS-CoV-2 Test Classification
The In Vitro Diagnostic (IVD) expert panel of the European Commission has released new scientific advice regarding SARS-CoV-2.

EU Initiative on Medical Devices and In-Vitro Diagnostics: A Targeted Evaluation
The European Commission has launched a public consultation as part of its targeted evaluation of the EU rules on medical devices and in-vitro diagnostics.

Meet Us at Arab Health 2025!
We are thrilled to announce that we will be attending Arab Health 2025, taking place from Monday, January 27, 2025, to Thursday, January 30, 2025, in Dubai.

MedNet EC-REP GmbH to Exhibit at MEDICA 2024 in Düsseldorf
We are excited to announce its participation at MEDICA 2024, the world’s leading trade fair for the medical industry, taking place from November 11th to 14th in Düsseldorf, Germany.
-250x250.jpg&w=256&q=75)
MedNet EC-REP GmbH Successfully Renews ISO 13485:2016 Certification
We are pleased to announce that MedNet EC-REP GmbH has successfully renewed its ISO 13485:2016 certification.